home / stock / prld / prld articles
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at ...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology compan...
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncolo...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated (NASDAQ:PRL...
STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage pre...
PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ:PRLD) ("Pre...
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at ...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematolo...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology compan...